The Zhitong Finance App learned that on August 28, Macfield (02041) announced that the company plans to sell 389.106 million shares globally, including 3.8911 million shares in Hong Kong and 35.195 million shares internationally. The offering date is from August 28 to September 2. The sale price is HK$15.42, 100 shares per lot, and the entry fee is approximately HK$1557.55. The company's global sale is expected to raise a total capital of HK$600 million, with a net capital raised of HK$496 million. Macfield is expected to be listed on the main board on September 7, 2026. Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited are co-sponsors.
In terms of this funding, about 35% will be used for R&D to enrich product lines; about 20% will be used to develop manufacturing centers and expand production capacity; about 20% will be used to improve sales and marketing capabilities; about 10% will be used for global strategic investments and acquisitions; about 5% will be used to upgrade IT infrastructure; and about 10% will be used for working capital.
Macfield is a global medical device provider that can meet the clinical needs of a wide range of clinical departments, wards and clinics within medical institutions, as well as community health centers, laboratories, and home care scenarios. As of March 31, 2026, the company's product portfolio includes more than 60 life support products, 110 minimally invasive interventional products, and 150 in vitro diagnostic products. These products come in a variety of models to meet various application needs. The company's products have covered more than 140 countries and regions around the world. In China, the company's products have covered more than 6,000 hospitals, including about 90% of level-III hospitals, covering 31 provinces, municipalities and autonomous regions.
According to information, from 2023 to 2025, the company's revenue increased from 1,313 billion yuan to 1,399 billion yuan, and further increased to 1,619 billion yuan, with a compound annual growth rate of about 11%, and a year-on-year increase of 15.7% in 2025. In the same period, the company's gross profit increased from 651 million yuan to 870 million yuan, and gross margin increased from 49.6% to 53.7%. The scale effect and product structure optimization achieved remarkable results. In addition, adjusted net profit reached 129 million yuan in 2025, and adjusted profit of 35 million yuan in the first three months of 2026, far exceeding 15.1 million yuan in the same period last year. Profit increased by more than 130% during the adjusted period; adjusted EBITDA also increased to 290 million yuan, with a compound growth rate of 38.9% between 2023 and 2025.